Xtacy Therapeutics Corp. TT5.F Stock
Xtacy Therapeutics Corp. Price Chart
Xtacy Therapeutics Corp. TT5.F Financial and Trading Overview
Xtacy Therapeutics Corp. stock price | 0.02 EUR |
Previous Close | 8.1 EUR |
Open | 8.05 EUR |
Bid | 8 EUR x N/A |
Ask | 8.2 EUR x N/A |
Day's Range | 8.05 - 8.05 EUR |
52 Week Range | 4.04 - 8.2 EUR |
Volume | 150 EUR |
Avg. Volume | 2 EUR |
Market Cap | 75.21M EUR |
Beta (5Y Monthly) | 0.939436 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.01 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | February 11, 2020 |
1y Target Est | N/A |
TT5.F Valuation Measures
Enterprise Value | 153.42M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.16636044 |
Price/Book (mrq) | 1.0183429 |
Enterprise Value/Revenue | 0.339 |
Enterprise Value/EBITDA | -256.253 |
Trading Information
Xtacy Therapeutics Corp. Stock Price History
Beta (5Y Monthly) | 0.939436 |
52-Week Change | 54.71% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.2 EUR |
52 Week Low | 4.04 EUR |
50-Day Moving Average | 7.22 EUR |
200-Day Moving Average | 5.17 EUR |
TT5.F Share Statistics
Avg. Volume (3 month) | 2 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 9.27M |
Float | 5.34M |
Short Ratio | N/A |
% Held by Insiders | 29.81% |
% Held by Institutions | 46.39% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 26, 2023 |
Most Recent Quarter (mrq) | March 26, 2023 |
Next Fiscal Year End | March 26, 2024 |
Profitability
Profit Margin | -0.96% |
Operating Margin (ttm) | -0.46% |
Gross Margin | 20.14% |
EBITDA Margin | -0.13% |
Management Effectiveness
Return on Assets (ttm) | -0.60% |
Return on Equity (ttm) | -5.83% |
Income Statement
Revenue (ttm) | 452.06M EUR |
Revenue Per Share (ttm) | 49.35 EUR |
Quarterly Revenue Growth (yoy) | 2.60% |
Gross Profit (ttm) | 91.08M EUR |
EBITDA | -598700 EUR |
Net Income Avi to Common (ttm) | -4347000 EUR |
Diluted EPS (ttm) | -0.44 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 777.2K EUR |
Total Cash Per Share (mrq) | 0.08 EUR |
Total Debt (mrq) | 78.35M EUR |
Total Debt/Equity (mrq) | 107.16 EUR |
Current Ratio (mrq) | 1.976 |
Book Value Per Share (mrq) | 7.905 |
Cash Flow Statement
Operating Cash Flow (ttm) | -11959000 EUR |
Levered Free Cash Flow (ttm) | -31164050 EUR |
Profile of Xtacy Therapeutics Corp.
Country | Germany |
State | MD |
City | Hunt Valley |
Address | 11126 McCormick Road |
ZIP | 21031 |
Phone | 410 229 1000 |
Website | https://www.tessco.com |
Industry | Communication Equipment |
Sector(s) | Technology |
Full Time Employees | 557 |
TESSCO Technologies Incorporated engages in manufacture and distribution of technology products and solutions for wireless infrastructure market in the United States and internationally. It operates in two segments, Carrier and Commercial. The company offers base station infrastructure products, including base station antennas, cable and transmission lines, small towers, lightning protection devices, connectors, power systems, enclosures, grounding products, jumpers, miscellaneous hardware products, and mobile antennas to build, repair, and upgrade wireless broadband systems. It also provides network systems products, such as fixed and mobile broadband radio equipment, wireless networking filtering and distributed antenna systems, two-way radios, and security and surveillance products. In addition, the company offers installation, test, and maintenance products comprising analysis equipment; and various frequency, voltage, and power-measuring devices, as well as tools, hardware, GPS and safety products, and replacement and component parts and supplies to install, tune, and maintain wireless communications equipment. The company sells its products to carrier and public network operators, tower owners, program managers, contractors and integrators, private system operators, federal governments, state and local governments, manufacturers, national solutions providers, and value-added resellers under the Ventev brand. TESSCO Technologies Incorporated was founded in 1982 and is headquartered in Hunt Valley, Maryland.
Q&A For Xtacy Therapeutics Corp. Stock
What is a current TT5.F stock price?
Xtacy Therapeutics Corp. TT5.F stock price today per share is 0.02 EUR.
How to purchase Xtacy Therapeutics Corp. stock?
You can buy TT5.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Xtacy Therapeutics Corp.?
The stock symbol or ticker of Xtacy Therapeutics Corp. is TT5.F.
Which industry does the Xtacy Therapeutics Corp. company belong to?
The Xtacy Therapeutics Corp. industry is Communication Equipment.
How many shares does Xtacy Therapeutics Corp. have in circulation?
The max supply of Xtacy Therapeutics Corp. shares is 83.8M.
What is Xtacy Therapeutics Corp. Price to Earnings Ratio (PE Ratio)?
Xtacy Therapeutics Corp. PE Ratio is now.
What was Xtacy Therapeutics Corp. earnings per share over the trailing 12 months (TTM)?
Xtacy Therapeutics Corp. EPS is -0.01 EUR over the trailing 12 months.
Which sector does the Xtacy Therapeutics Corp. company belong to?
The Xtacy Therapeutics Corp. sector is Technology.